Immutep Ltd (IMM) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.233x

Based on the latest financial reports, Immutep Ltd (IMM) has a cash flow conversion efficiency ratio of -0.233x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-33.50 Million ≈ $-23.71 Million USD) by net assets (AU$143.64 Million ≈ $101.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Immutep Ltd (IMM) liquidity interval to measure how many days the company can operate on defensive assets alone.

Immutep Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Immutep Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Immutep Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Immutep Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Nebag ag
SW:NBEN
0.001x
Titania Holding AB Series B
ST:TITA-B
-0.051x
Emami Paper Mills Limited
NSE:EMAMIPAP
0.211x
Kandi Technologies Group Inc
NASDAQ:KNDI
-0.359x
Cellid Co. Ltd
KQ:299660
-0.031x
GCL Global Holdings Ltd Ordinary Shares
NASDAQ:GCL
-0.003x
Q.S.I Co. LTD
KQ:066310
0.001x
Phinergy Ltd
TA:PNRG
-0.265x

Annual Cash Flow Conversion Efficiency for Immutep Ltd (2004–2025)

The table below shows the annual cash flow conversion efficiency of Immutep Ltd from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see IMM market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$143.64 Million
≈ $101.63 Million
AU$-62.05 Million
≈ $-43.90 Million
-0.432x -135.12%
2024-06-30 AU$189.52 Million
≈ $134.10 Million
AU$-34.82 Million
≈ $-24.64 Million
-0.184x +30.12%
2023-06-30 AU$136.47 Million
≈ $96.56 Million
AU$-35.88 Million
≈ $-25.39 Million
-0.263x +18.17%
2022-06-30 AU$94.08 Million
≈ $66.57 Million
AU$-30.23 Million
≈ $-21.39 Million
-0.321x -33.47%
2021-06-30 AU$73.27 Million
≈ $51.84 Million
AU$-17.64 Million
≈ $-12.48 Million
-0.241x +26.04%
2020-06-30 AU$33.30 Million
≈ $23.56 Million
AU$-10.84 Million
≈ $-7.67 Million
-0.326x +48.07%
2019-06-30 AU$24.39 Million
≈ $17.26 Million
AU$-15.29 Million
≈ $-10.82 Million
-0.627x -176573.57%
2018-06-30 AU$33.52 Million
≈ $23.72 Million
AU$-11.89K
≈ $-8.42K
0.000x +99.89%
2017-06-30 AU$26.53 Million
≈ $18.77 Million
AU$-8.51 Million
≈ $-6.02 Million
-0.321x -0.12%
2016-06-30 AU$35.32 Million
≈ $24.99 Million
AU$-11.31 Million
≈ $-8.00 Million
-0.320x -1.53%
2015-06-30 AU$24.69 Million
≈ $17.47 Million
AU$-7.79 Million
≈ $-5.51 Million
-0.315x +49.92%
2014-06-30 AU$22.59 Million
≈ $15.99 Million
AU$-14.23 Million
≈ $-10.07 Million
-0.630x -14.85%
2013-06-30 AU$29.25 Million
≈ $20.70 Million
AU$-16.04 Million
≈ $-11.35 Million
-0.548x -6.56%
2012-06-30 AU$37.16 Million
≈ $26.29 Million
AU$-19.12 Million
≈ $-13.53 Million
-0.515x -190.62%
2011-06-30 AU$55.10 Million
≈ $38.99 Million
AU$-9.76 Million
≈ $-6.90 Million
-0.177x +54.00%
2010-06-30 AU$16.79 Million
≈ $11.88 Million
AU$-6.46 Million
≈ $-4.57 Million
-0.385x +62.96%
2009-06-30 AU$1.81 Million
≈ $1.28 Million
AU$-1.88 Million
≈ $-1.33 Million
-1.039x -76.06%
2008-06-30 AU$2.63 Million
≈ $1.86 Million
AU$-1.55 Million
≈ $-1.10 Million
-0.590x +27.67%
2007-06-30 AU$4.08 Million
≈ $2.89 Million
AU$-3.33 Million
≈ $-2.36 Million
-0.816x -2.03%
2006-06-30 AU$6.32 Million
≈ $4.47 Million
AU$-5.05 Million
≈ $-3.57 Million
-0.800x -40.92%
2005-06-30 AU$8.34 Million
≈ $5.90 Million
AU$-4.73 Million
≈ $-3.35 Million
-0.568x +48.43%
2004-06-30 AU$5.13 Million
≈ $3.63 Million
AU$-5.64 Million
≈ $-3.99 Million
-1.100x --

About Immutep Ltd

AU:IMM Australia Biotechnology
Market Cap
$55.20 Million
AU$78.01 Million AUD
Market Cap Rank
#21574 Global
#761 in Australia
Share Price
AU$0.05
Change (1 day)
+8.16%
52-Week Range
AU$0.04 - AU$0.46
All Time High
AU$0.68
About

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more